FiltersReset Filters

With box warnings

Without box warnings

Branded

Generic

7 results

gazyva
(obinutuzumab)
Genentech, Inc.
Usage: GAZYVA is indicated for treating chronic lymphocytic leukemia (CLL) in combination with chlorambucil, and for follicular lymphoma (FL) in combination with bendamustine or chemotherapy, followed by monotherapy. It is used for relapsed/refractory FL post-rituximab and for untreated stage II bulky, III or IV FL.
kesimpta
(ofatumumab)
Novartis Pharmaceuticals Corporation
Usage: KESIMPTA is indicated for treating relapsing forms of multiple sclerosis (MS) in adults, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.
ocrevus
(ocrelizumab)
Genentech, Inc.
Usage: OCREVUS is indicated for the treatment of relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as primary progressive MS in adults.
ocrevus zunovo
(ocrelizumab and hyaluronidase)
Genentech, Inc.
Usage: OCREVUS ZUNOVO is indicated for treating relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as primary progressive MS, in adults.
rituxan
(rituximab)
Genentech, Inc.
Usage: RITUXAN is indicated for the treatment of various conditions including Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Rheumatoid Arthritis (RA), Granulomatosis with Polyangiitis (GPA), Microscopic Polyangiitis (MPA), and Pemphigus Vulgaris (PV) in adults and pediatric patients, as specified.
rituxan hycela
(rituximab and hyaluronidase)
Genentech, Inc.
Usage: RITUXAN HYCELA is indicated for adult patients with relapsed/refractory and previously untreated follicular lymphoma, as maintenance therapy or after CVP chemotherapy. It treats diffuse large B-cell lymphoma in combination with CHOP, and chronic lymphocytic leukemia with fludarabine and cyclophosphamide. Not for non-malignant conditions.
ruxience
(rituximab-pvvr)
Pfizer Laboratories Div Pfizer Inc
Usage: RUXIENCE is indicated for adult patients with relapsed or refractory non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL), rheumatoid arthritis (RA), and granulomatosis with polyangiitis and microscopic polyangiitis, often in combination with other therapies, depending on the specific condition and patient response.

CD20-directed Cytolytic Antibody class drugs

gazyva

kesimpta

ocrevus

ocrevus zunovo

rituxan

rituxan hycela

ruxience